Search research articles
Contact Us
Filters
Showing results (151-160 of 169) with videos related to
Page
of 17
Sort By:
JCO Precision Oncology
|
November 9, 2020
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs
Michael L Cheng, Mark T A Donoghue, François Audenet, et al.
JCO Precision Oncology
|
June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
Nima Almassi, Karissa Whiting, Antoun Toubaji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
European Urology
|
April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma
Carissa E Chu, Ziyu Chen, Karissa Whiting, et al.
Nature
|
May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitness
David Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Cancer Discovery
|
August 7, 2014
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
Eliezer M Van Allen, Kent W Mouw, Philip Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2018
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
Gopa Iyer, Arjun V Balar, Matthew I Milowsky, et al.
Cancer Discovery
|
June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations
Sumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma
Jonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
JCO Precision Oncology
|
May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer
Andrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 169) with videos related to
Sort By:
Page
of 17
JCO Precision Oncology
|
November 9, 2020
Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs
Michael L Cheng, Mark T A Donoghue, François Audenet, et al.
JCO Precision Oncology
|
June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
Nima Almassi, Karissa Whiting, Antoun Toubaji, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
European Urology
|
April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma
Carissa E Chu, Ziyu Chen, Karissa Whiting, et al.
Nature
|
May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitness
David Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Cancer Discovery
|
August 7, 2014
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
Eliezer M Van Allen, Kent W Mouw, Philip Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2018
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
Gopa Iyer, Arjun V Balar, Matthew I Milowsky, et al.
Cancer Discovery
|
June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations
Sumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma
Jonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
JCO Precision Oncology
|
May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer
Andrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Page
of 17